Mixed Serum-deprived and Normal Adipose-derived Mesenchymal Stem Cells Against Acute Lung Ischemia-reperfusion Injury in Rats
Overview
Authors
Affiliations
Background: This study hypothesized that combined serum-deprived (Sd) and healthy (He) adipose-derived mesenchymal stem cell (ADMSC) therapy is superior to either alone in reducing acute lung ischemia-reperfusion injury (ALIRI).
Methods: Adult male Sprague-Dawley (SD) rats (n = 30) were equally randomized into group 1 (sham control), group 2 (ALIRI + culture medium), group 3 (ALIRI + intravenous autologous 1.2 × 10(6) He-ADMSCs at 30 minute, 6 h, and 24 h following lung ischemia/reperfusion for 45 minutes/72 hours, respectively), group 4 (ALIRI + 1.2 × 10(6) Sd-ADMSCs at identical time points after ischemia/reperfusion), and group 5 (ALIRI + 1.2 × 10(6) combined Sd-ADMSC/He-ADMSC 1:1).
Results: Blood oxygen saturation (%) was lowest in group 2, lower in groups 3 to 5 than in group 1, and lower in group 5 than in group 1, whereas right ventricular systolic pressure (RVSP) showed a reverse pattern among the five groups (all p < 0.001). Additionally, changes in histological scoring of lung parenchymal damage, inflammatory and apoptotic biomarkers showed identical pattern compared to that of RVSP in all groups (all p < 0.001). Protein expressions of VCAM-1, ICAM-1, oxidative stress, TNF-α, nuclear factor-κB, and number of CD68 + cells were highest in group 2, higher in groups 3 to 5 than in group 1, and higher in groups 3 and 4 than in group 5, whereas NQO-1 and HO-1 activities and number of CD31 + and vWF + cells showed opposite changes compared with those of inflammatory biomarkers (all p < 0.001).
Conclusion: Combined Sd-ADMSC/He-ADMSC therapy offered superior benefit to either option alone in minimizing rodent ALIRI through suppressing oxidative stress and inflammatory reaction.
Fu Q, Gao Q, Jiao S, Da F, Guo J, Liu Y Regen Ther. 2024; 27:398-407.
PMID: 38694446 PMC: 11061648. DOI: 10.1016/j.reth.2024.04.001.
Chen Y, Yang C, Chiang J, Sung P, Shao P, Huang C Cell Transplant. 2023; 32:9636897231211067.
PMID: 38078417 PMC: 10714882. DOI: 10.1177/09636897231211067.
Ko S, Li Y, Shao P, Chiang J, Sung P, Chen Y Stem Cell Rev Rep. 2023; 19(8):2852-2868.
PMID: 37632641 DOI: 10.1007/s12015-023-10611-4.
Lin K, Yeh J, Shao P, Chiang J, Sung P, Huang C J Cell Mol Med. 2023; 27(8):1110-1130.
PMID: 36942326 PMC: 10098301. DOI: 10.1111/jcmm.17723.
Yue Y, Yeh J, Chiang J, Sung P, Chen Y, Liu F Stem Cell Res Ther. 2022; 13(1):186.
PMID: 35526048 PMC: 9080206. DOI: 10.1186/s13287-022-02857-5.